长春新碱治疗乳腺癌的临床疗效观察

The clinical observation of vincristine in treatment of breast cancer

目的：探讨长春新碱在乳腺癌患者中的临床疗效。方法：选取2004年1月~2010年5月的184例乳腺癌患者为研究对象,将其根据化疗方式不同分为对照组（米托蒽醌组）92例和观察组（米托蒽醌联合长春新碱组）92例,后将两组患者的治疗总有效率、不良反应发生率及治疗后1个月和3个月的生存质量评分进行统计比较。结果：观察组的治疗总有效率及治疗后1个月和3个月的生存质量评分均高于对照组,P均〈0.05,差异有统计学意义,但两组患者不良反应发生率比较,P〉0.05,差异无统计学意义。结论：长春新碱在乳腺癌患者中的临床疗效好,不良反应未见升高,可改善患者的生存质量。

Objective： To investigate the clinical efficacy of vincristine in the treatment of breast cancer. Methods： 184 cases of breast cancer from January 2004 to May 2010 were chosen as research object. They were divided into 92 cases of the control group （mitoxantrone group） and 92 cases of the observation group （mitoxantrone combined vincristine group） according to different chemotherapy ways. And compared the total efficiency, the incidence of adverse reactions and treatment after 1 month and quality of life score of 3 months for the two groups. Results： The total effective rate of treatment and quality of life scores 1 month and 3 months after treatment for the observation group were higher than the control group, P0.05, there was significant difference. But the incidence of adverse reactions of two groups compared, P0.05, there was no significant difference. Conclusion： Vincristine in the treatment of breast cancer has good clinical efficacy, there is no increase in adverse reactions, it can improve the patient＇s quality of life.